SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY.

ALD2510 - Alderaan Biotechnology

Simulect (basiliximab) - Novartis

https://jitc.bmj.com//content/9/Suppl_2/A898

Jemila Houacine 1; Anne Marie-Cardine 2; Aude Le Roy 1; Jérôme Giustiniani 3; Riad Abes 1; Anne-Sophie Chrétien 4; Stéphane Fattori 4; Laurent Gorvel 4; Armand Bensussan 2; Daniel Olive 4; Arnaud Foussat 1

Oct 1, 2021